Vir Biotechnology (NASDAQ:VIR)报告季度每股亏损$(0.76)，优于分析师普遍预期的$(0.87)，增长了12.64%。较去年同期的每股亏损$(0.86)提高了11.63%。公司报告季度销售额为$12.37M，超过了分析师普遍预期的$8.14M，增长了52.01%。与去年同期的销售额$16.79M相比，减少了26.29%。
以上内容来自Benzinga Earnings专栏，原文如下：
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.87) by 12.64 percent. This is a 11.63 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $12.37 million which beat the analyst consensus estimate of $8.14 million by 52.01 percent. This is a 26.29 percent decrease over sales of $16.79 million the same period last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。